PDL BioPharma, Inc.
PDLIV
NASDAQ
Recommendation
Prev Close
--
Volume
--
Avg Vol (90D)
--
Market Cap
--
Dividend & Yield
--
52-Week Range
-- - --
P/E (TTM)
--
EPS (TTM)
| 08/31/2020 | 06/30/2020 | 03/31/2020 | 12/31/2019 | 09/30/2019 | |
|---|---|---|---|---|---|
| Net Income | -- | -1,030.82% | -574.90% | -- | -169.59% |
| Total Depreciation and Amortization | -- | -28.91% | -23.27% | -- | -57.16% |
| Total Amortization of Deferred Charges | -- | -89.50% | -85.44% | -- | 3.60% |
| Total Other Non-Cash Items | -- | 423.24% | 468.27% | -- | 107.82% |
| Change in Net Operating Assets | -- | -512.13% | -821.20% | -- | -26.46% |
| Cash from Operations | -- | -2.95% | -521.24% | -826.67% | -161.02% |
| Capital Expenditure | -- | -17.36% | -121.43% | -- | 53.03% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 127.40% | 7.52% | -- | 3,337.71% |
| Cash from Investing | -- | 126.98% | 7.14% | 2.70% | 1,909.76% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | 25.32% | 56.59% | -- | -231.30% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | 81.25% | -- |
| Other Financing Activities | -- | -- | -181.98% | -- | -- |
| Cash from Financing | -- | 27.03% | 9.41% | -317.81% | -1,029.66% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | 73.59% | -64.98% | -1,476.78% | 75.00% |